Researchers at KAUST and Oxford used an organic electrochemical transistor sensor to measure three forms of alpha-synuclein inside neuron-derived vesicles isolated from blood, achieving 90.9% accuracy in a blinded 59-participant sample from the Oxford Discovery cohort. The 40-minute assay distinguished Parkinson's profiles from healthy controls and included participants with isolated REM sleep behavior disorder, a recognized prodromal state. The work is retrospective and not yet a standalone clinical test, with sensitivity and specificity not reported.
Key Points
- Transistor sensor read three alpha-synuclein forms in 40 minutes
- 90.9% accuracy across 59 blinded Oxford Discovery cohort samples
- Retrospective design; sensitivity and specificity figures not disclosed
Longevity Analysis
Neurodegeneration begins years before movement symptoms appear, and current diagnosis depends on clinical observation after substantial dopaminergic loss has already occurred. Reading protein signals carried out of neurons in extracellular vesicles moves detection upstream, into the window where behavioral, metabolic and sleep-related interventions still have tissue to protect. The inclusion of REM sleep behavior disorder participants is notable: disturbed sleep is one of the earliest legible signals the nervous system sends, and a blood-based readout that corresponds to it would give that signal measurable weight rather than leaving it as an isolated observation.
Original published by Longevity.Technology, by Kyle Umipig.